A total of 190 patients aged between 18-65 years diagnosed with plaque psoriasis are planned to be included in the study. The study consists of three periods:~Screening period: Within 28 days before baseline visit (-28 days to 0 days)~Treatment period: 4 weeks~Follow-up period with observation: 4 weeks~The study is planned to last a maximum of 12 weeks for each patient. Study consists of 6 visits: baseline (day 1), week 2 and week 4, and week 6 and week 8, which is a follow-up period with observation.
This Phase II study was designed as a multicenter, randomized, double-blind, placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and tolerabilityGN-037 versus clobetasol 17-propionate and placebo in patients diagnosed with mild to moderate plaque psoriasis at least 6 months ago